HOWL werewolftx.com: Enterprise Value to EBITDA Ratio

Graphic logo of Werewolf Therapeutics, Inc. (HOWL)

Werewolf Therapeutics (HOWL) bases its research centers in Massachusetts, outsourcing drug production to third-party contractors to minimize technical failures. However, the high cost of testing and the risk of adverse drug reactions create financial pressure. This chart of exchange-traded quotes shows an EV/EBITDA of 0.00. The business is currently spending its existing reserves as planned, relying on a significant liquidity cushion to drive innovation.

Werewolf Therapeutics Inc. - HOWL Total Company Value to Operating Income Before Depreciation Ratio (period 11/23/2025 - 11/10/2026)

Summary analytical data breakdowns for werewolftx.com (HOWL)

- stock price and consensus target price:
Stock Quotes Werewolf Therapeutics, Inc.|HOWL - Average Forecast Price
- company stock capitalization data:
Market Valuation Werewolf Therapeutics, Inc.|HOWL - Value Adjusted for Debt and Cash
- business book valuation details:
Book Value per Share Werewolf Therapeutics|HOWL - Book Valuation of Business|Market Value to Book Value Ratio werewolftx.com|HOWL - Cumulative Company Assets
- debt and solvency information:
Debt to Equity Werewolf Therapeutics|HOWL - Long-Term Debt to Equity Ratio|Short-Term Debt to Equity Ratio Werewolf Therapeutics, Inc.|HOWL - Company Aggregate Debts|Debt to Book Capitalization Ratio Werewolf Therapeutics, Inc.|HOWL - Company Long-Term Indebtedness|Company Short-Term Debt Werewolf Therapeutics|Quick Liquidity Indicator werewolftx.com
- financial results and valuation multiples details:
HOWL - Annual Net Income|Future Profit Werewolf Therapeutics|HOWL - Market Price to Net Income Ratio|Forward P/E Multiple Werewolf Therapeutics, Inc.|HOWL - Growth-Adjusted Payback Ratio|EV/EBITDA Multiple Werewolf Therapeutics, Inc.|HOWL - Profit before interest, taxes and amortization|Earnings per share for the last twelve months Werewolf Therapeutics|HOWL - Earnings per share for the trailing year|Quarterly EPS earnings growth werewolftx.com|HOWL - Earnings growth in current year|Net earnings per share growth forecast for next year Werewolf Therapeutics
Fundamental company analysis:HOWL (Werewolf)
Original product of Werewolf Therapeutics Inc.

Werewolf Therapeutics (HOWL) is scaling its PREDATOR technology for targeted tumor destruction, aiming for a significant share of the immuno-oncology market. By analyzing the company's EV/EBITDA ratio on the chart, an investor assesses the total enterprise value, including debt, relative to operating profit, which allows for the determination of the asset's real value and the identification of hidden liquidity deficit risks during sharp price fluctuations.

Competitor analysis for Werewolf Therapeutics

ImmunityBio Corp - Enterprise Value to EBITDA Ratio|Immunocore Corp (IMCR) - Company Value to EBITDA|JANX: Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation RCUS (arcusbio.com)|ZYME: EV/EBITDA Multiple|TNGX - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Iovance|Enterprise Value to EBITDA Ratio Immatics Biotechnologies (IMTX)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Xencor, Inc. (XNCR)|Enterprise Value to EBITDA Ratio compasstherapeutics.com CMPX|Replimune - Enterprise Value to EBITDA Ratio|EV/EBITDA Multiple Lyell LYEL|IPHA - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|PYXS (Pyxis Oncology, Inc.) - Enterprise Value to Operating Income Before Depreciation|cgen.com (CGEN) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA iobiotech.com (IOBT)|Enterprise Value to EBITDA Ratio STRO|INKT - Enterprise Value to EBITDA Multiple|Enterprise Value to EBITDA Ratio IMMX (Immix Biopharma, Inc.)|Enterprise Value to Operating Income Before Depreciation Ratio ALXO|EV/EBITDA Multiple CUE (Cue Biopharma)|Business Value to Operating Income Before Depreciation PDSB|Sonnet BioTherapeutics Holdings Inc. - EV/EBITDA Multiple|Company Value to EBITDA MAIA Biotech|Liminatus Pharma Corp (LIMN) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|LAVA Therapeutics - Business Value to Operating Income Before Depreciation|NXTC (NextCure, Inc.) - EV/EBITDA Multiple|EV/EBITDA Multiple Leap Tx|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Intensity Therapeutics (INTS)|SNSE: Company Value to Operating Income Before Depreciation Ratio|Synthetic Biologics - Enterprise Value to EBITDA Ratio|Gritstone bio Inc. (GRTS) - Company Value to EBITDA|KA: Enterprise Value to EBITDA Ratio|neximmune.com (NEXI) - Enterprise Value to EBITDA Ratio|TSBX: EV/EBITDA Multiple|Company Value to EBITDA Vaccinex Inc. (VCNX)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Harpoon Tx